CHEMCLIN DIAGNOSTICS CO., LTD. Chemclin Diagnostics Co., Ltd. Stock
Equities
688468
CNE100005311
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.43 CNY | +1.64% |
|
+13.61% | -31.14% |
| Sales 2022 | 465M 64.27M 88.48M | Sales 2023 | 445M 61.51M 84.69M | Capitalization | 4.33B 598M 823M |
|---|---|---|---|---|---|
| Net income 2022 | 153M 21.13M 29.1M | Net income 2023 | 147M 20.3M 27.96M | EV / Sales 2022 | 6.07 x |
| Net cash position 2022 | 973M 134M 185M | Net cash position 2023 | 684M 94.49M 130M | EV / Sales 2023 | 8.18 x |
| P/E ratio 2022 |
24.9
x | P/E ratio 2023 |
29.2
x | Employees | 690 |
| Yield 2022 |
3.66% | Yield 2023 |
-
| Free-Float | 35.88% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.64% | ||
| 1 week | +13.61% | ||
| Current month | +1.78% | ||
| 1 month | +1.78% | ||
| 3 months | -12.69% | ||
| 6 months | -28.07% | ||
| Current year | -31.14% |
1 week
6.69
7.51
1 month
6.127.57
Current year
5.8010.90
1 year
5.8012.94
3 years
5.8030.40
5 years
5.8031.77
10 years
5.8031.77
| Managers | Title | Age | Since |
|---|---|---|---|
Lin Li
CEO | Chief Executive Officer | 62 | 07-12-31 |
Yan Ling Huang
DFI | Director of Finance/CFO | 49 | 07-12-31 |
Hong Yan Fu
BRD | Director/Board Member | 50 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Jie Zhang
BRD | Director/Board Member | 47 | 19-09-10 |
Jie Zhang
BRD | Director/Board Member | 71 | 19-10-23 |
Lin Li
CEO | Chief Executive Officer | 62 | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 7.43 | +1.64% | 6,089,005 |
| 24-04-29 | 7.31 | +4.88% | 6,699,887 |
| 24-04-26 | 6.97 | +2.20% | 3,002,319 |
| 24-04-25 | 6.82 | +1.04% | 3,363,896 |
| 24-04-24 | 6.75 | +0.75% | 3,506,623 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.
Calendar
2024-08-22
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -31.14% | 412M | |
| -0.60% | 12.63B | |
| -9.59% | 7.67B | |
| +1.82% | 5.42B | |
| +0.02% | 4.57B | |
| -51.89% | 3.51B | |
| +6.42% | 2.59B | |
| -14.59% | 2.05B | |
| -8.29% | 1.79B | |
| +1.67% | 1.77B |
- Stock Market
- Equities
- 688468 Stock
